Watchlist Price Alert

Vaxcyte Inc. (PCVX)

NASDAQ: PCVX · Real-Time Price · USD

31.16

-0.29 (-0.92%)

At close: May 09, 2025, 3:59 PM

31.26

0.32%

After-hours: May 09, 2025, 05:49 PM EDT

-0.92% (1D)

Bid	28.88
Market Cap	4.02B
Revenue (ttm)	n/a
Net Income (ttm)	-463.93M
EPS (ttm)	-3.8
PE Ratio (ttm)	-8.2
Forward PE	-6.24
Analyst	Buy

Ask	34
Volume	1,568,989
Avg. Volume (20D)	2,401,528.9
Open	31.29
Previous Close	31.45
Day's Range	31.08 - 33.47
52-Week Range	27.66 - 121.06
Beta	1.27

About PCVX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PCVX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PCVX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

+8.45%

Vaxcyte shares are trading higher after the compan... Unlock content with Pro Subscription

1 week ago

+0.43%

Vaxcyte shares traded higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.

News

4 weeks ago · zacks.com

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

1 month ago · zacks.com

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

1 month ago · seekingalpha.com

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It...

1 month ago · benzinga.com

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte Inc. PCVX on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (P...

2 months ago · seekingalpha.com

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Con...